HOOKIPA Pharma to Present at Upcoming Conferences in September
September 09 2020 - 7:30AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that HOOKIPA’s management team will participate in the
following virtual investor conferences in September:
- H.C. Wainwright 22nd Annual Global Investment Conference,
September 14-16, 2020 Presentation: Monday,
September 14, 2020 at 10:30 AM ET
- Morgan Stanley Virtual Global Healthcare Conference, September
14-18, 2020 Presentation: Tuesday, September 15,
2020 at 12:30 PM ET
- BofA Global Healthcare Conference 2020, September 16-18, 2020
Presentation: Wednesday, September 16, 2020 at
2:10 PM BST
The live audio webcast of the presentation held
at the H.C. Wainwright 22nd Annual Global Investment Conference,
Morgan Stanley Virtual Global Healthcare Conference and BofA Global
Healthcare Conference will be available within the Investors &
Media section of HOOKIPA’s website at
https://ir.hookipapharma.com/events. An archived replay will be
accessible for 30 days following the event.
About
HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics targeting infectious diseases and cancers based
on its proprietary arenavirus platform that reprograms the body’s
immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, non-replicating (VaxWave®) and replicating (TheraT®),
induce robust antigen-specific CD8+ T cells and
pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral
vectors target antigen presenting cells in vivo to activate the
immune system. Both technologies enable repeat administration to
augment and refresh immune responses. As a monotherapy, our
replicating arenavirus technology has the potential to induce CD8+
T cell response levels previously not achieved by other
immuno-therapy approaches.
HOOKIPA’s non-replicating prophylactic
Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2
clinical trial for patients awaiting kidney transplantation. To
expand its infectious disease portfolio, HOOKIPA entered into a
collaboration and licensing agreement with Gilead Sciences, Inc. to
research arenavirus-based functional cures for HIV and chronic
Hepatitis B infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The lead
replicating arenavirus oncology product candidates, HB-201 and
HB-202, are in development for the treatment of Human Papilloma
Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201
was initiated in December 2019. The HB-202 IND application was
cleared by the FDA in June 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
HOOKIPA Forward Looking
Statements
Certain statements set forth in this press
release constitute “forward-looking” statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements can be identified by terms such
as “believes,” “expects,” “plans,” “potential,” “would” or similar
expressions and the negative of those terms. Such forward-looking
statements involve substantial risks and uncertainties that could
cause HOOKIPA’s research and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including HOOKIPA’s
programs’ early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, HOOKIPA’s ability to
successfully establish, protect and defend its intellectual
property, risks relating to business interruptions resulting from
the coronavirus (COVID-19) disease outbreak or similar public
health crises, the impact of COVID-19 on the enrollment of patients
and timing of clinical results for HB-101 and other programs, and
other matters that could affect the sufficiency of existing cash to
fund operations and HOOKIPA’s ability to achieve the milestones
under the agreement with Gilead. HOOKIPA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of the
company in general, see HOOKIPA’s quarterly report on Form 10-Q for
the quarter ended June 30, 2020 which is available on the Security
and Exchange Commission’s website at www.sec.gov and HOOKIPA’s
website at www.hookipapharma.com.
Investors and others should note that we announce material
financial information to our investors using our investor relations
website (https://ir.hookipapharma.com/), SEC filings, press
releases, public conference calls and webcasts. We use these
channels, as well as social media, to communicate with our members
and the public about our company, our services and other issues. It
is possible that the information we post on social media could be
deemed to be material information. Therefore, we encourage
investors, the media, and others interested in our company to
review the information we post on the U.S. social media channels
listed on our investor relations website.
For further information, please contact:
Media |
Investors |
Nina Waibel |
Matt Beck |
Senior Director - Communications |
Executive Director - Investor Relations |
nina.waibel@hookipapharma.com |
matthew.beck@hookipapharma.com |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024